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In addition to direct effects on virus infectivity, anti-
bodiesmediate antibody-dependent cellular cytotox-
icity (ADCC), the killing of an antibody-coated virus-
infected cell by cytotoxic effector cells. Although
ADCC has been suggested to protect against HIV,
the relationship between HIV-specific ADCC anti-
bodies at the time of HIV exposure and infection
outcome in humans remains to be assessed. We
evaluated the ADCC activity of passively acquired
antibodies in infants born to HIV-infected mothers.
ADCC levels were higher in uninfected than infected
infants, although not significantly. Increase in ADCC
antibody activity in infected infants was associated
with reduced mortality risk. Infant ADCC positively
correlated with the magnitude of IgG1 binding, and
IgG1 levels were associated with survival in infected
infants. Infant IgG3-bindingantibodieswerenot asso-
ciated with infected infant survival. These data sug-
gest a therapeutic benefit of pre-existing HIV-specific
ADCC antibodies and support a role for eliciting
ADCC-mediating IgG1 in HIV vaccines.
INTRODUCTION
Rational design of an effective vaccine against HIV requires
understanding the functional characteristics of antibodies cap-
able of preventing virus transmission or providing a thera-
peutic benefit. One function of antibodies is antibody-dependent
cellular cytotoxicity (ADCC), and HIV-specific ADCC activity has
been suggested to provide a protective and/or therapeutic effect
in multiple settings. Evidence for a therapeutic effect in humans
comes from studies showing that de novo ADCC antibody re-
sponses are inversely associated with viral load and higher in500 Cell Host & Microbe 17, 500–506, April 8, 2015 ª2015 Elsevier Inviral controllers than progressors (reviewed in Lewis, 2014).
However, human data on whether or not ADCC antibodies are
protective if present at the time of exposure (pre-existing anti-
bodies) are more limited. In the RV144 vaccine trial, vaccine-
induced ADCC antibodies correlated with reduced infection
risk in an exploratory analysis of individuals with low plasma
IgA (Haynes et al., 2012). Furthermore, ADCC activity in the index
case has been associated with protection in the setting of
mother-infant transmission. There, high maternal breast milk
HIV-specific ADCC activity correlated with reduced risk of
infant infection via breastfeeding (Mabuka et al., 2012). Addi-
tional support for the protective role of ADCC antibodies comes
from studies in macaques that have shown vaccine-induced
ADCC responses correlate with lower viral loads and/or delayed
disease progression following simian immunodeficiency virus
(SIV) challenge (reviewed in Lewis, 2014). Collectively, these
findings support the hypothesis that ADCC antibodies present
at the time of HIV exposure may have a role in protecting against
HIV acquisition or modulating viral load in those who become
infected. However, translating results from macaque studies
and hypothesis-generating studies in humans to more definitive
human studies is critical for determining the importance of pre-
existing antibodies in protection.
HIV mother-to-child transmission (MTCT) is a unique setting in
which to examine the protective role of ADCC antibodies present
at exposure because maternal IgG crosses the placenta during
pregnancy. Thus, infants born to HIV-infected mothers have
HIV-specific antibodies present in circulation at birth that may
provide protection during virus exposure, particularly during
breastfeeding. Several early studies of ADCC in MTCT showed
no correlation of infant or maternal ADCC and infection risk (Bro-
liden et al., 1993; Jenkins et al., 1994; Ljunggren et al., 1990; Ma-
bondzo et al., 1995; Pugatch et al., 1997). However, these
studies may have been limited in their ability to detect a protec-
tive effect of ADCC antibodies based on techniques available,
including (1) use of lab-adapted viruses that do not represent
transmitted strains; (2) infant infection status was often deter-
mined by ELISA at 15 months, and thus, timing of infectionc.
A B Figure 1. Infant ADCC Antibody Responses
(A) Passively acquired infant ADCC responses are
shown in relation to infection outcome. Results are
normalized to a positive control (HivIg), and data
are represented as mean ± SEM.
(B) Kaplan-Meier estimates for infected infants
with infant ADCC antibody activity greater than or
equal to infected infant cohort median ADCC ac-
tivity (solid line) and infected infants with ADCC
antibody activity less than median (dashed line).(including in utero infections) could not be verified; and (3)
infant ADCC activity was measured at various ages up until 2
years, at which point passively transferred antibodies may not
be relevant and de novo responses may have been measured.
With advances in infant diagnosis/follow-up and improvements
in ADCC methods, we are now more aptly positioned to deter-
mine if pre-existing ADCC antibodies in HIV-exposed infants in-
fluence virus acquisition or disease progression.
In this study, we evaluated passively acquired ADCC antibody
activity in plasma near the time of birth from infants born to
HIV-infected mothers. We hypothesized that this pre-existing
HIV-specific ADCC antibody activity in infants would provide a
protective and therapeutic benefit to infants exposed to HIV
via breastfeeding. We found that both ADCC activity and the
magnitude of IgG1 but not IgG3 antibody binding were signifi-
cantly associated with a decreased risk of mortality in infants
who became infected. These results suggest that pre-existing
HIV-specific IgG1-mediated ADCC activity may provide a thera-
peutic benefit in individuals who become infected and is an
important component to consider for a HIV vaccine.RESULTS
Passively Acquired ADCC Antibody Activity and Infant
Infection Risk
To investigate the impact of HIV-specific, ADCC-mediating
passively acquired antibodies on infant infection and disease
progression, we examined ADCC responses in 72 infants who
were HIV RNA negative at birth and were continually exposed
to HIV via breastfeeding. We focused on infants with a plasma
sample from the first week of life because passively acquired an-
tibodies are the highest at this time and because the first weeks
of life are when infants are at the highest risk of breastfeeding
infection (Nduati et al., 2000). Of the 72 infants whomet the study
criteria, 21 became infected and were detected as HIV positive
at the following visits: week 2 (n = 1), week 6 (n = 10), week 14
(n = 1), month 6 (n = 1), and months 7–24 (n = 8).
To select a representative envelope antigen to measure infant
ADCC activity against, we first ran eight HIV gp120s from diverse
clades against six plasmas. This experiment suggested that
although absolute values of ADCC activity varied, a similar
pattern of ADCC antibody activity was observed across enve-
lope antigens (Figure S1A). We selected the BL035 gp120
because it was representative of the results with the different
gp120s (Figure S1B) and because it was cloned from an early in-
fant virus in the cohort.
We then measured the ADCC antibody activity of the 72 infant
plasmas against BL035. Overall, uninfected infants had higherCellmean ADCC activity than infected infants (36.7% versus
26.3%; Figure 1A); however, this association was not statistically
significant (p = 0.12). In a logistic regression controlling for
maternal viral load, a known risk factor for MTCT, there was
not a significant association between infant ADCC activity and
risk of infection (odds ratio [OR]: 0.99, 95% CI 0.97 to 1.01, p =
0.26). When analysis was restricted to infants infected within
the first 6 weeks of life (when passive ADCC antibody levels
are highest), similar results were obtained: uninfected infants
had higher passive ADCC levels than infants who became in-
fected, but the difference was not statistically significant (Figures
S2A and S2B).
Passively Acquired ADCC Antibody Activity and Survival
in HIV-Infected Infants
While sterilizing immunity is the gold standardmeasure of protec-
tion, pre-existing ADCC antibodies may also provide a therapeu-
tic benefit in those who acquire HIV. Thus, as part of a pre-spec-
ifiedanalysis plan,weexamined time tomortality after infection to
determine the impact of passively acquired ADCC antibodies on
clinical outcome. In the 21 infected infants, there were eight
deaths during follow-up (38%). In a Cox-proportional hazards
model, each 10% increase in ADCC antibody activity was
associated with a 49.1% reduction in risk of mortality (p =
0.033). Additionally, when comparing Kaplan-Meier survival
functions for infected infants with ADCC greater than or equal
to the infected infant cohort median with those infants who had
ADCC antibody activity less than the median, the survival curves
were significantly different (X2 = 4.22, p = 0.04; Figure 1B).
Set point viral loads (Richardson et al., 2003) were only available
for a subset of the infected infants. Among this smaller group
(n = 10), there was a trend for a negative association between
pre-existing ADCC antibody activity and set point viral load
(r = 0.59, p = 0.074).
Maternal ADCC Antibody Activity and Infant
Infection Risk
In many published MTCT studies, maternal antibodies were
measured in an attempt to define immune correlates of protec-
tion in infants. To address whether maternal antibody activity
correlates with protection and whether maternal antibodies
provide a similar measure of ADCC activity as passively acquired
antibodies in the infants, ADCC activity in the 72 corresponding
mothers was examined. Plasma from the third trimester or
delivery was chosen based on the fact that the majority of pas-
sive antibody transfer occurs late in pregnancy and thus the
maternal antibody repertoire during this time shouldmost closely
resemble the passively acquired antibodies present in infants atHost & Microbe 17, 500–506, April 8, 2015 ª2015 Elsevier Inc. 501
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Figure 2. Maternal ADCC Antibody Responses
(A) Correlation between maternal and infant ADCC antibody responses.
(B) Maternal ADCC responses are shown in relation to infant infection outcome. Results are normalized to a positive control (HivIg), and data are represented as
mean ± SEM.
(C) Kaplan-Meier estimates for infected infants with maternal ADCC antibody activity greater than or equal to the maternal transmitter cohort median ADCC
activity (solid line) and infected infants with maternal ADCC antibody activity less than median (dashed line).birth (reviewed in Palmeira et al., 2012). Maternal ADCC antibody
activity correlated with infant responses (r = 0.75, p < 0.0001;
Figure 2A), and maternal ADCC levels were higher than those
in the infants, with a median fold-difference in ADCC activity
of 1.7. However, unlike their infants, themothers had nearly iden-
tical ADCC antibody levels of 44.2% for transmitters and 42.1%
for non-transmitters (p = 0.81; Figure 2B). This relationship re-
mained non-significant when controlling for maternal viral load
in a logistic regression analysis (OR: 1.00, 95% CI: 0.99 to
1.02, p = 0.76). Additionally, in contrast to infant samples, there
was not a significant association between maternal ADCC activ-
ity and infected infant survival in a Cox-proportional hazards
model (hazard ratio [HR]: 0.99, p = 0.30) or when comparing
Kaplan-Meier estimates (Figure 2C), suggesting a unique role
of passively acquired antibodies in the observed association
with survival.
Passively Acquired HIV-Specific Neutralizing and
Binding Antibodies in HIV-Exposed Infants
To determine whether the association between passively ac-
quired ADCC activity and infected infant survival was unique to
the ADCC antibody function, we also examined the impact of
neutralizing antibodies (NAbs) on infant infection and survival us-
ing available IC50 data for eight viruses representing four clades
(Lynch et al., 2011). In the 72 infants included in this study, NAb
breadth and potency were not associated with infant infection
status (Figures S3A and S3B), as observed with a larger group
of infants in the prior study (Lynch et al., 2011). There was amod-
erate, but significant, association between infant ADCC activity
and NAb breadth (r = 0.50, p < 0.0001) and potency (r = 0.57,
p < 0.0001) (Figures S3C and S3D). Nevertheless, in a Cox-pro-
portional hazards model, there was not a significant association
between passively acquired NAb breadth (HR: 0.86, p = 0.35) or
potency (HR: 0.94, p = 0.34) and infected infant survival. Addi-
tionally, there was no correlation between neutralization IC50
and infected infant survival for each of the eight individual viruses
(data not shown).
We also examined HIV-specific IgG binding titers (end point
titers [EPTs]), which encompass neutralizing and non-neutral-
izing antibodies, including those that mediate ADCC activity.
These titers correlated with ADCC antibody activity (r = 0.59,
p < 0.0001) but similarly did not differ between infected and un-
infected infants (p = 0.94) (Figures S3E and S3F). We observed a502 Cell Host & Microbe 17, 500–506, April 8, 2015 ª2015 Elsevier Intrend in association between these EPTs and infant survival (HR:
0.80, p = 0.091).
Passively Acquired IgG1 and IgG3 in Infant ADCC
We next sought to understand whether a particular IgG subclass
of passively transferred antibodies was associated with the
survival benefit observed in infected infants. ADCC is reported
to be predominately mediated by IgG1 and IgG3, and thus, we
focused on these subclasses. Infant ADCC antibody activity
was strongly correlatedwith IgG1 antibody binding, asmeasured
by binding to cell surface gp120 (r = 0.92; p < 0.0001; Figure 3A).
There was no difference in surface IgG1 antibody binding be-
tween infected (mean log2MFI: 9.51) and uninfected infants
(mean log2MFI: 9.46) (p = 0.82; Figure 3B). In infected infants,
however, there was a strong association between surface IgG1
binding and survival (HR: 0.24; p = 0.005), with higher log2MFI
associated with increased survival in a Cox-proportional hazards
model. Furthermore, comparing Kaplan-Meier survival functions
for infected infants with a log2MFI greater than or equal to the
cohort median with those infants who had log2MFI activity less
than the cohort median, the survival curves were significantly
different (c2 = 7.74, p = 0.005; Figure 3C).
IgG3 binding was measured by ELISA because, similar to pre-
vious reports (Smalls-Mantey et al., 2012), we could not detect
IgG3 surface binding by the flow-cytometry-based method.
IgG1 surface binding MFI and gp120-specific ELISA binding
titers correlated (data not shown), demonstrating that the assays
provide similar measures. Overall, HIV-specific IgG3 was de-
tected in 34 (47.22%) of infant samples. IgG3 did not correlate
with infant ADCC activity (r = 0.16, p = 0.18; Figure 3D). Simi-
larly, IgG3 binding was not associated with infant infection (p =
0.58; Figure 3E) or survival in infected infants (Figure 3F).
Kinetics of ADCC Antibody Responses in Infected
Infants
In macaques, higher passive NAb levels have been linked to
more robust de novo responses (Haigwood et al., 2004; Ng
et al., 2010), raising the possibility that the passive ADCC activity
in infants was a surrogate measure for de novo ADCC responses
contributing to infection control. To test this possibility, longitu-
dinal plasma samples from six infected infants in the study
were tested for ADCC activity. The highest passively acquired
ADCC antibody activity was detected within the first week ofc.
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Figure 3. IgG1 and IgG3 HIV-Specific Responses in Infants
(A and D) Correlation of infant ADCC antibody activity and IgG1 log2MFI responses (A) or IgG3 log2EPT (D).
(B and E) IgG1 (B) or IgG3 (E) responses in relation to infant infection status; mean ± SEM are shown.
(C and F) Kaplan-Meier estimates for infected infants with IgG1 log2MFI greater than or equal to infected infant cohort median (solid line) and infected infants with
IgG1 log2MFI less than cohort median (dashed line) (C) or IgG3 levels detectable at a 1:50 dilution (solid line) versus undetectable (dashed line) (F).life and declined to undetectable levels in all six infants prior to a
subsequent increase in de novo ADCC activity after infection
(Figures 4A–4F). De novo ADCC antibody activity could be de-
tected as early as 2 months post-infection; however, responses
appeared delayed in infants infected within 6 weeks of birth. In
four cases, the maximum de novo ADCC activity was higher
than that of the passively acquired activity measured at birth.
There was no correlation between passively acquired ADCC
antibody activity measured at birth and maximum de novo activ-
ity measured after infection (r =0.14, p = 0.79; Figure 4G), sug-
gesting that our finding showing an association with passive
ADCC antibodies and infant outcome was not confounded by
an association between passive and de novo responses.
DISCUSSION
Defining the role of HIV-specific antibodies in protection in natu-
ral infection settings is important to inform rational vaccine
design. Insights from animal models and studies of viral control
in chronic HIV infections provide indirect support for ADCC anti-
bodies in protection, but these settings do not directly address
the efficacy of antibodies present at the time of exposure in hu-
mans. In this study, we sought to understand whether pre-exist-
ing ADCC antibody activity provided protection from infection
and/or disease progression in HIV-exposed infants. Here we
report an association between pre-existing HIV-specific ADCC
antibody activity and better clinical outcome in humans.
We found that uninfected infants had higher ADCC antibody
activity than infected infants; however, this association was
not statistically significant. Our power to detect a truly significant
difference was limited by the small numbers of infected infants,
particularly when considering only those infants infected in
the first 6 weeks of life. Prior studies of similar or smaller size
also did not detect a significant association between ADCC anti-
body activity and infant infection risk, although these studies
were limited by the lack of plasma samples from the most rele-Cellvant window for measuring protection, lack of relevant envelope
antigens, and/or imprecise measures of infection timing (Broli-
den et al., 1993; Jenkins et al., 1994; Ljunggren et al., 1990;
Pugatch et al., 1997). Thus, larger studies using well-timed sam-
ples tested against antigen representing circulating viruses are
needed to clarify if higher pre-existing ADCC activity in infants
is a significant correlate of protection from infection.
A correlate of protection was evident when examining clinical
outcome. In infected infants, each 10% increase in ADCC activ-
ity was associated with a 49.1% reduction in the risk of death.
Interestingly, two older studies also observed a positive associ-
ation between ADCC antibody activity and clinical outcome in
infected infants even though ADCC activity was measured at
various ages (Broliden et al., 1993; Ljunggren et al., 1990). Due
to this variation in sample timing, the contribution of de novo
versus pre-existing ADCC antibodies in protection was unclear,
and de novo responses may have been primarily measured
in these older studies. In our results, de novo ADCC levels did
not correlate with passively acquired activity, further supporting
the role of pre-existing antibodies in the survival benefit we
observed. As binding titers measure a contribution of both
non-neutralizing (including ADCC) and neutralizing antibodies,
the role of ADCC antibodies in survival was also indirectly sup-
ported by the trend between IgG binding titers and survival.
Additionally, the observation that passive NAbs were not associ-
ated with outcome suggests that the infant ADCC activity
measured was not a surrogate for overall HIV-specific antibody
activity but rather was specific for the ability of antibodies to
mediate ADCC.
In addition to the positive association between pre-existing
ADCC antibody activity and infected infant survival, we also
observed a trend toward a negative correlation between infant
ADCC and set point viral load. Unfortunately, our ability to detect
a true association between ADCC and set point was limited
by the sparse set point viral load data for the infected infants.
Nevertheless, the observed trend supports the hypothesis thatHost & Microbe 17, 500–506, April 8, 2015 ª2015 Elsevier Inc. 503
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Figure 4. Kinetics of ADCC Antibody Responses in HIV-Infected Infants
(A–F) ADCC antibody activity in plasma in longitudinal samples from six HIV-infected infants. Three had passively acquired ADCC activity less than infected infant
cohort median ([A]–[C]) and three had activity greater thanmedian ([D]–[F]). Black arrow indicates estimated time of infection defined as themidpoint between the
last negative and first positive HIV DNA test. Unfilled dot represents first HIV-DNA-positive test. Results represent mean ± SD for two independent experiments in
duplicate.
(G) Correlation between the passively acquired ADCC antibody response (measured in the first week of life) andmaximum de novo ADCC activity measured after
infection, for the six infants.pre-existing antibodies may have acted to clear infected cells,
thereby lowering set point viral loads and protecting against dis-
ease progression. This hypothesis is supported by the fact that
infant set point viral loads are predictive of HIV disease progres-
sion (Obimbo et al., 2009; Palumbo et al., 1998) and is consistent
with macaque vaccine studies showing pre-existing ADCC anti-
body activity is associated with lower viremia in macaques
infected by virus challenge (reviewed in Lewis, 2014). The asso-
ciation between pre-existing ADCC activity and viral control
should be analyzed in future human vaccine studies to under-
stand if ADCC provides a therapeutic effect in individuals who
become infected.
Interestingly, our results suggest that IgG1, and not IgG3, was
important for the ADCC activity and survival effect observed in
this study. While IgG1 and IgG3 are major mediators of ADCC
activity, recent data from RV144 suggested that vaccine-in-
duced IgG3 was important for the ADCC activity and protective
effect observed in that trial (Chung et al., 2014; Yates et al.,
2014). In our study, IgG3 levels did not correlate with risk of infant
infection or survival in infected infants. IgG1 levels, however, did
directly correlate with survival in infected infants. This difference
between our study and the RV144 results highlights differences
in antibodies elicited by natural infection versus the ALVAC/
AIDSVAX vaccination method and suggests that IgG1 ADCC-
mediating antibodies could be an important component of an
effective vaccine response.
De novo ADCC activity was detected as early as 2 months
post-infection and 6 months of age in our study, which is earlier
than has previously been reported for infant HIV-specific ADCC
antibodies (Pugatch et al., 1997). Although numbers are small,
there was evidence that responses were delayed in infants in-
fected within 6 weeks of birth. A delay in de novo responses504 Cell Host & Microbe 17, 500–506, April 8, 2015 ª2015 Elsevier Inmay be due to the detrimental impact of early HIV infection on
the developing immune system (reviewed in Tobin and Aldro-
vandi, 2013). While adult ADCC antibody responses have been
suggested to peak at approximately 6 months post-infection
(Dugast et al., 2014), infant de novo responses continued to in-
crease for over a year post-infection in three infants. These
ADCC levels exceeded those acquired by passive transfer, and
this difference from adults may be due to the higher peak viral
loads and thus increased antigenic stimulation observed in in-
fants (Richardson et al., 2003).
Unexpectedly, transmitting and non-transmitting mothers had
nearly identical ADCC levels, and in those mothers who trans-
mitted, maternal ADCC antibody levels were not predictive of in-
fant survival. This difference between maternal and infant ADCC
activity may be partially explained by the timing of maternal sam-
pling. We sampled maternal plasma primarily from the third
trimester of pregnancy as the majority of passive antibody trans-
fer occurs during this time. However, as reports suggest that the
majority of passive transfer occurs within the last few weeks of
pregnancy (Palmeira et al., 2012), samples from earlier in the
third trimester may not be representative of the infant antibody
repertoire at birth, particularly if there is variation in gestational
age. This variation in the timewhen the infant was born in relation
to when the maternal antibodies were sampled may have al-
lowed us to discriminate the effect of maternal versus passive
antibodies in protection. A more intriguing possibility is that the
differences between maternal and infant ADCC are due to differ-
ences in passive transfer of antibodies to the infants. IgG sub-
class and the glycosylation profile of antibodies impact ADCC
activity and have also been suggested to be differentially trans-
ferred across the placenta (Ackerman et al., 2013; Ferrante et al.,
1990; Hashira et al., 2000; Simister, 2003; Williams et al., 1995;c.
Wren et al., 2013), suggesting that maternal ADCC antibody
levels may not always be indicative of infant repertoires. In any
case, these results have important implications given that prior
studies often focused on the relationship between maternal anti-
body responses, rather than infant responses, and protection.
The observed differences in infant and maternal responses sug-
gest that maternal samples may not be an accurate surrogate
measure of passively acquired responses in infants for some
antibody functions such as ADCC.
In summary, we show that pre-existing HIV-specific ADCC
antibody activity is associated with survival in HIV-infected in-
fants. This association was detectedwhenmeasuring infant pas-
sive antibody levels but not maternal antibodies. Infected infant
survival was also associated with HIV-specific IgG1, and not
IgG3, levels and was not linked to de novo ADCC activity. These
data support a role for developing vaccines that are designed to
elicit ADCC-mediating IgG1 antibodies.
EXPERIMENTAL PROCEDURES
Study Design
Plasma samples were from the Nairobi Breastfeeding Trial conducted in the
mid-1990s, before antiretrovirals were used for prevention of MTCT (Nduati
et al., 2000). Infants were tested for HIV DNA at birth, 6 weeks, 14 weeks,
and every 3 months until 2 years of age. For those infants who tested positive,
samples prior to the first HIV-DNA-positive test were tested for HIV RNA to
more precisely define infection timing. Time of infection was estimated as
the midpoint between the last negative HIV DNA or RNA test and the first pos-
itive test. Infant samples were selected for study based on the following
criteria: (1) HIV DNA and RNA negative at birth, (2) breastfed forR3 months,
(3) remained HIV-negative for at least 6 months and throughout all follow-up
if in the uninfected arm, and (4) availability of a plasma sample from the first
week of life. Based on these criteria, 72 infants were included, 21 of who
became infected during follow-up. Corresponding maternal plasma samples
from the third trimester of pregnancy (n = 69) or delivery (n = 3) were also
selected for testing. Longitudinal plasma samples were analyzed for six in-
fants. These infants were chosen based on the availability of multiple samples
prior to and post infection. The ethical review committee of the Kenyatta Na-
tional Hospital Institutional Review Board, the Institutional Review Board of
the University of Washington and the Institutional Review Board of the Fred
Hutchinson Cancer Research Center gave permission to conduct the Nairobi
Breastfeeding Clinical Trial.
Rapid Fluorometric Antibody-Dependent Cellular Cytotoxicity Assay
ADCC was measured using the rapid fluorometric ADCC (RFADCC) assay as
previously described (Go´mez-Roma´n et al., 2006; Mabuka et al., 2012). Target
cells were coated with BL035.W6M.Env.C1 (BL035) gp120 (Immune Technol-
ogy Corp.). Plasma samples were run at 1:5,000, which detected a wide range
of ADCC activity while avoiding a prozone effect. Samples were run in dupli-
cate and in comparison studies, all samples were run with the same peripheral
bloodmononuclear cell (PBMC) donors to reduce donor variability. Infant sam-
ples were run three times in duplicate with two PBMC donors, and maternal
samples were run two times in duplicate with one donor. Pooled IgG from
HIV-positive individuals, HivIg (NIH AIDS Reagent Program), was used as a
positive control. In a pilot study, four infant plasmas and two plasma pools
(HivIg and pooled plasma from 30 chronically infected Kenyans [VA Pool])
were tested in duplicate against target cells coated with different gp120 anti-
gens (BL035.W6M.Env.C1, MG505.W0M.Env.H3, MK184.W0M.Env.G3, Bal,
WITO4160, YU2, CAP210.2.00, andDu422.1; Immune TechnologyCorp). Final
reports of ADCC activity were normalized to HivIg, which was set at 100%.
HIV-Specific Total IgG and IgG3 ELISAs
HIV-envelope-specific ELISAs were performed as previously described (Ma-
buka et al., 2012), with the following modifications. ELISA plates were coated
with BL035 gp120 at 25 ng/well (total IgG ELISA) or 50 ng/well (IgG3 ELISA).CellPlasma dilutions started at 1:25,000 (total IgG) or 1:50 (IgG3) and were titrated
2-fold. If IgG EPT was less than 1:25,000, 2-fold dilutions were conducted
starting at 1:1,000. For total IgG, samples were detected with goat anti-human
IgG-HRP diluted 1:3,000. IgG3 samples were incubated with mouse anti-hu-
man IgG3-biotin (SouthernBiotech) at 2 mg/ml and then with streptavidin-
HRP at 1 mg/ml. EPT was defined as the plasma reciprocal dilution at which
the average OD value was greater than two times the average OD value of
background measured against HIV-uninfected plasma. Samples were run in
duplicate two times. If the sample did not reach EPT at the lowest dilution
tested, the EPT was set as the midpoint between 0 and the lowest dilution
tested.
Detection of IgG1 Cell-Surface Binding
To measure the magnitude of HIV-specific IgG1 binding to gp120-coated
cells, the following protocol was adapted from Smalls-Mantey, et al. (2012).
CEM-NKr cells were coated with BL035 gp120 at 15 mg/1 million cells. Next,
25,000 CEM-NKr cells were incubated with 1:1,000 patient plasma run in
duplicate. Samples were washed and stained with mouse anti-human IgG1-
Alexa-488 at a 1:1,000 dilution (SouthernBiotech). Median fluorescence inten-
sity (MFI) was quantified by flow cytometry.
Statistical Analysis
The statistical plan for infant and maternal ADCC antibody responses were
established prior to data collection and based on literature suggesting
ADCC activity may impact acquisition and clinical outcome, thus negating
the need to adjust for multiple comparisons (Savitz and Olshan, 1995).
Following the observed positive association between infant ADCC antibody
activity and survival, experiments and analyses were conducted to further
explore themechanism and antibody subclass responsible for the effect. Inde-
pendent groups were compared by two-sided Welch’s t test. Logistic regres-
sion analysis was used to compare independent groups and control for
maternal viral load. Survival analyses were conducted using Cox-proportional
hazards models and Kaplan-Meier estimates with log rank tests. Correlations
were estimated by the Spearman rank method. ELISA and MFI data were log2
transformed, and viral load data were log10 transformed for all analyses. Sta-
tistical analyses were performed using STATA version 12.1 (College Station).
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